- Enprofylline
-
- $59.00
-
2026-04-22
- CAS:41078-02-8
- Purity: 98.37%
- Supply Ability: 10g
- ENPROFYLLINE
-
- $1.00
-
2020-01-15
- CAS:41078-02-8
- Min. Order: 1KG
- Purity: 99.0%
- Supply Ability: 100kg
|
| | ENPROFYLLINE Basic information |
| Product Name: | ENPROFYLLINE | | Synonyms: | 3-Propylxanthfine;Enprofyllilie;3-propyl-7H-purine-2,6-dione;3-propyl-7H-purine-2,6-quinone;1H-Purine-2,6-dione, 3,9-dihydro-3-propyl-;ENPROPHYLLINE;3-Propyl-1H-purine-2,6(3H,7H)-dione;3-N-PROPYLXANTHINE | | CAS: | 41078-02-8 | | MF: | C8H10N4O2 | | MW: | 194.19 | | EINECS: | 255-201-8 | | Product Categories: | | | Mol File: | 41078-02-8.mol |  |
| | ENPROFYLLINE Chemical Properties |
| Melting point | 287-289 °C | | density | 1.38 g/cm3 | | storage temp. | 2-8°C | | solubility | DMSO: soluble | | form | solid | | pka | 10.26±0.20(Predicted) | | color | white | | CAS DataBase Reference | 41078-02-8 |
| Hazard Codes | Xn | | Risk Statements | 20/21/22 | | Safety Statements | 36 | | WGK Germany | 3 | | RTECS | UO8439700 |
| | ENPROFYLLINE Usage And Synthesis |
| Description | 3-Propylxanthine is a xanthine derivative that antagonizes adenosine receptors (Kis = 44, 32, and 6.3 μM for A1, A2A, and A2B, respectively) and cAMP phosphodiesterase (Ki = 42 μM). Through these actions, 3-propylxanthine induces smooth muscle relaxation, blocks smooth muscle contraction and VEGF secretion driven by adenosine receptor agonists, and reduces bronchial hyperresponsiveness. | | Uses | Bronchodilator. | | Uses | Enprofylline is a xanthine lacking adenosine receptor antagonism. | | Definition | ChEBI: Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic n
uropathy. | | in vivo | Enprofylline increases heart rate (HR). Injection of Enprofylline (7.5 and 30 mg/kg) increases HR in male WT mouse from 529±23 to 590±20 and 562±20 after the low and high dose, respectively[3].
A high dose of Enprofylline (30 mg/kg) also decreases temperature compared with saline injection in female (but not in males) WT mice, but a low dose (7.5 mg/kg) has little effect on mouse temperature[3]. | Animal Model: | A1RKO mice (were cross-bred to C57BL/6 mice for six generations) and A2ARKO mice (were backcrossed to C57BL/6 mice for more than 10 generations)[3] | | Dosage: | 30 mg/kg | | Administration: | Intraperitoneally injected (bolus) at 2-h intervals | | Result: | Increased HR in male WT mouse from 529±23 to 590±20 and 562±20 after the low (7.5 mg/kg) and high dose (30 mg/kg), respectively. |
| | IC 50 | A2B receptor: 7 μM (Ki) | | References | [1] J LINDEN. Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells.[J]. Molecular Pharmacology, 1999, 56 4: 705-713.
[2] K. OGAWA T. S K Takagi. Mechanism of xanthine-induced relaxation of guinea-pig isolated trachealis muscle[J]. British Journal of Pharmacology, 1989, 97 2: 542-546. DOI: 10.1111/j.1476-5381.1989.tb11983.x
[3] U SCHWABE M J L D Ukena. Xanthine derivatives as antagonists at A1 and A2 adenosine receptors.[J]. Naunyn-Schmiedeberg’s archives of pharmacology, 1985, 330 3: 212-221. DOI: 10.1007/bf00572436
[4] BIRGITTE HIER. Contraction-induced secretion of VEGF from skeletal muscle cells is mediated by adenosine.[J]. American journal of physiology. Heart and circulatory physiology, 2010: H857-62. DOI: 10.1152/ajpheart.00082.2010
[5] G H KOTER. Effect of theophylline and enprofylline on bronchial hyperresponsiveness.[J]. Thorax, 1989, 44 12: 1022-1026. DOI: 10.1136/thx.44.12.1022 |
| | ENPROFYLLINE Preparation Products And Raw materials |
|